Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay.

@article{Stellrecht2014PremarketEO,
  title={Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay.},
  author={Kathleen A Stellrecht and Alvin A Espino and Vincente P Maceira and Seela M Nattanmai and Shafiq A Butt and Danielle Wroblewski and George E. Hannett and Kimberlee Aruda Musser},
  journal={Journal of clinical microbiology},
  year={2014},
  volume={52 5},
  pages={1423-8}
}
Clostridium difficile-associated diarrhea is a well-recognized complication of antibiotic use. Historically, diagnosing C. difficile has been difficult, as antigen assays are insensitive and culture-based methods require several days to yield results. Nucleic acid amplification tests (NAATs) are quickly becoming the standard of care. We compared the performance of two automated investigational/research use only (IUO/RUO) NAATs for the detection of C. difficile toxin genes, the IMDx C. difficile… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…